Since 2007, twelve separate GWAS have been conducted within these four cohorts (Table 1). The primary traits are breast cancer [16 (link)], pancreatic cancer [43 (link)], glaucoma [44 (link)], endometrial cancer [17 (link)], colon cancer [19 (link)], glioma [45 (link)], prostate cancer [18 (link)], type 2 diabetes [14 (link)], coronary heart disease [15 (link)], kidney stones, gout and mammographic density [20 (link)]. These studies were genotyped on six different arrays (Table 1) at four different genotyping centers (National Cancer Institute, Broad Institute, University of Southern California and Rosetta/Merck). Standard quality control filters for call rate, Hardy-Weinberg equilibrium, and other measures were applied to the genotyped SNPs and/or samples. In total, these GWAS data sets comprise 20,769 participants including 11,522 from NHS, 934 subjects from NHSII, 7,018 subjects from HPFS and 1,305 subjects from PHS.
Free full text: Click here